Description

"This fund primarily invests in common stocks. Typically, at least 80% of its assets are dedicated to companies actively involved in the discovery, advancement, production, and sale of biotechnology-related offerings (products, services, and processes), as well as companies positioned to significantly gain from scientific and technological breakthroughs in biotechnology. The fund's holdings include both U.S. and foreign companies. Investment decisions are guided by comprehensive fundamental analysis, evaluating factors like each issuer's financial stability, competitive position, and broader market and economic conditions. It is structured as a non-diversified fund."